|Mr. William Lis||CEO, Pres & Director||740.85k||N/A||53|
|Ms. Mardi C. Dier||CFO & Exec. VP||603.43k||354.25k||53|
|Dr. John T. Curnutte M.D., Ph.D.||Exec. VP of R&D||575.19k||N/A||65|
|Mr. Tao Fu||Chief Commercial & Bus. Officer and Exec. VP||580.72k||N/A||45|
|Mr. Jeet Mahal||VP of Bus. Devel.||N/A||N/A||N/A|
Portola Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics for patients in the areas of thrombosis, other hematologic disorders, and inflammation. The company is developing Betrixaban, an oral once-daily inhibitor of Factor Xa that is in Phase III clinical stage for extended duration VTE prophylaxis in acute medically ill patients for 35 days of in-hospital and post-discharge use; Andexanet alfa, a recombinant protein, which is in Phase III and IV stages for reverse anticoagulant activity in patients treated with fXa inhibitor; and Cerdulatinib, an orally available dual kinase inhibitor, which is in Phase IIa clinical stage for hematologic, blood, cancers, and inflammatory disorders. It also develops Syk-selective inhibitors in pre-clinical stage for allergic conjunctivitis. Portola Pharmaceuticals, Inc. has collaboration agreements with Bristol-Myers Squibb; Pfizer Inc.; Bayer Pharma, AG; Janssen Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; and Dermavant Sciences GmbH. The company was founded in 2003 and is headquartered in South San Francisco, California.
Portola Pharmaceuticals, Inc.’s ISS Governance QualityScore as of August 1, 2017 is 7. The pillar scores are Audit: 2; Board: 3; Shareholder Rights: 7; Compensation: 9.